8-K: PTC Therapeutics Sells Remaining Evrysdi Royalty Interest

PTC Therapeutics, Inc. has sold its retained royalty interest in Roche's Evrysdi product to Royalty Pharma for $240 million upfront cash and potential future payments.

Summary

• PTC Therapeutics, Inc. (the Company) entered into Amendment No. 2 to its Amended and Restated Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV (RPI) on December 29, 2025.
• The Company sold its retained interest in sales-based royalty payments on worldwide net sales of Roche's Evrysdi (risdiplam) product to RPI.
• The transaction provides PTC Therapeutics with $240.0 million in upfront cash consideration.
• Three potential additional cash purchase price payments of $20.0 million each are contingent upon RPI receiving specific Assigned Royalty Payments in future calendar years.
• These contingent payments are conditioned on RPI receiving more than $347.0 million in 2027, $363.0 million in 2028, and $379.0 million in 2029.
• The retained interest sold was 9.5111% of the Royalty before the 2020 Assigned Royalty Cap and 16.6666% of the Royalty after the cap.
• As a result of this sale, RPI now owns 100% of the Royalty, and PTC Therapeutics owns 0%.

Sentiment

Score: 7

Explanation: The transaction provides a significant immediate cash infusion and potential future payments, strengthening the Company's financial position. However, it also divests a long-term asset, removing future uncapped royalty upside, which balances the overall sentiment.

Positives

• Secured $240.0 million in immediate upfront cash, significantly enhancing liquidity.
• Potential to receive up to an additional $60.0 million through three contingent payments, providing further non-dilutive capital.
• Monetized a future royalty stream, de-risking the Company's financial position from the variability of future Evrysdi sales.

Negatives

• Relinquished all future uncapped royalty income from Evrysdi sales, potentially limiting long-term revenue upside from this asset.
• Contingent payments are not guaranteed and depend on Evrysdi sales reaching specific thresholds, introducing an element of uncertainty for future cash inflows.

Risks

• The Company's ability to receive the three potential additional cash purchase price payments of $20.0 million each is contingent upon RPI receiving more than $347.0 million of Assigned Royalty Payments in 2027, $363.0 million in 2028, and $379.0 million in 2029, respectively. Failure to meet these thresholds would result in the Company not receiving these payments.

Future Outlook

The Company has fully monetized its royalty interest in Evrysdi, securing immediate capital and potential future contingent payments. The future financial impact will depend on the deployment of the upfront cash and whether the specified Evrysdi sales thresholds are met in 2027, 2028, and 2029 to trigger the additional payments.

Management Comments

• Pierre Gravier, Chief Financial Officer, signed the report on behalf of PTC Therapeutics, Inc.

Industry Context

The monetization of future royalty streams is a common strategic financing tool in the biotechnology and pharmaceutical industries. Companies often use such transactions to secure non-dilutive capital for pipeline development, debt reduction, or general corporate purposes, especially for assets that have reached a mature commercial stage or where the company wishes to de-risk future revenue variability.

Comparison to Industry Standards

• Royalty monetization deals are a standard practice, with companies like BioMarin Pharmaceutical and Sarepta Therapeutics having engaged in similar transactions to fund R&D or strengthen balance sheets.
• The structure of upfront cash combined with contingent payments based on sales milestones is typical for such agreements, balancing immediate liquidity with potential upside participation.
• The specific royalty percentages and thresholds are unique to this agreement but reflect market valuations for established pharmaceutical assets like Evrysdi, which treats Spinal Muscular Atrophy (SMA).

Stakeholder Impact

• Shareholders: Benefit from immediate cash infusion, which can be used for pipeline investment, debt reduction, or other strategic initiatives, potentially reducing the need for dilutive financing.
• Employees: Enhanced financial stability could support ongoing research and development efforts and job security.
• Creditors: Improved liquidity and balance sheet strength may positively impact creditworthiness.

Next Steps

• The full text of Amendment No. 2 will be filed as an exhibit to the Company's annual report on Form 10-K for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

The sale of the remaining Evrysdi royalty interest provides a substantial immediate cash infusion of $240 million and potential future payments, strengthening the company's balance sheet. However, it also removes a long-term, uncapped revenue stream, which could impact future growth projections. Investors should hold to assess how this capital is deployed and its impact on the company's overall strategic direction and pipeline development.

Keywords

PTC Therapeutics, Royalty Pharma, Evrysdi, risdiplam, royalty sale, biotechnology, pharmaceuticals, SMA, Spinal Muscular Atrophy, asset monetization, financing